Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$1.43 USD
+0.01 (0.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.44 +0.01 (0.70%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CKPT 1.43 +0.01(0.70%)
Will CKPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CKPT based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CKPT
Checkpoint Therapeutics files to sell 7.76M shares of common stock for holders
Analysts’ Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics GAAP EPS of -$3.17 misses by $0.49, revenue of $0.1M misses by $0.02M
Checkpoint Therapeutics reports FY23 EPS ($3.17), consensus ($2.66)
CKPT Stock Earnings: Checkpoint Therapeutics Misses EPS, Misses Revenue for Q4 2023